AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme
Fill the form to download Workflow Comparison Study with AQUIOS CL Flow Cytometer
Innovation In CD4 Testing
HIV Advanced Disease Management
More than a third of people starting ART have advanced HIV disease, and an increasing number of patients develop an advanced HIV after disengaging from care.
HIV Diagnosis Becomes up to Four Times Faster Thanks to This Invention
HIV/AIDS Africa’s most vulnerable can benefit from simple test which monitors disease progression, enabling the comprehensive treatment programs.
AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme
The AQUIOS CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Program.
Case Study: London Health Sciences Centre (LHSC)
AQUIOS CL provides faster times to first result, faster turnaround times and faster total elapsed times, with fewer total steps and less hands-on time.**These reagents provide identification and enumeration of the following lymphocyte subset populations:
- total CD3+, CD3+CD4+,CD3+CD8+, CD3+CD4+/CD3+CD8+ (ratio only) lymphocyte percentages and absolute counts;
- CD45+ absolute count; and
- CD45+ Low SS (lymphocytes) percentage and absolute count.